메뉴 건너뛰기




Volumn 21, Issue 24, 2015, Pages 5439-5444

Alchemist trials: A golden opportunity to transform outcomes in early-stage non-small cell lung cancer

(13)  Govindan, Ramaswamy a   Mandrekar, Sumithra J b   Gerber, David E c   Oxnard, Geoffrey R d   Dahlberg, Suzanne E e   Chaft, Jamie f   Malik, Shakun g   Mooney, Margaret g   Abrams, Jeffrey S g   Jänne, Pasi A d   Gandara, David R h   Ramalingam, Suresh S i   Vokes, Everett E j  


Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; NIVOLUMAB; PLACEBO; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

EID: 84954190434     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0354     Document Type: Review
Times cited : (102)

References (23)
  • 2
    • 80455123686 scopus 로고    scopus 로고
    • Pathology of lung cancer
    • Travis WD. Pathology of lung cancer. Clin Chest Med 2011;32:669-92.
    • (2011) Clin Chest Med , vol.32 , pp. 669-692
    • Travis, W.D.1
  • 3
    • 79960889662 scopus 로고    scopus 로고
    • Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study
    • Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42.
    • (2011) Lancet Oncol , vol.12 , pp. 735-742
    • Zhou, C.1    Wu, Y.L.2    Chen, G.3    Feng, J.4    Liu, X.Q.5    Wang, C.6
  • 5
    • 2342624080 scopus 로고    scopus 로고
    • EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
    • Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
    • (2004) Science , vol.304 , pp. 1497-1500
    • Paez, J.G.1    Jänne, P.A.2    Lee, J.C.3    Tracy, S.4    Greulich, H.5    Gabriel, S.6
  • 7
    • 13244262942 scopus 로고    scopus 로고
    • Adjuvant treatment of lung cancer: Current status and potential applications of new regimens
    • Le Chevalier T, Lynch T. Adjuvant treatment of lung cancer: current status and potential applications of new regimens. Lung Cancer 2004;46:S33-9.
    • (2004) Lung Cancer , vol.46 , pp. S33-S39
    • Le Chevalier, T.1    Lynch, T.2
  • 8
    • 33747847740 scopus 로고    scopus 로고
    • Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant navelbine international trialist association [ANITA]): A randomised controlled trial
    • Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-27.
    • (2006) Lancet Oncol , vol.7 , pp. 719-727
    • Douillard, J.Y.1    Rosell, R.2    De Lena, M.3    Carpagnano, F.4    Ramlau, R.5    Gonzáles-Larriba, J.L.6
  • 9
    • 20544455590 scopus 로고    scopus 로고
    • Vinorelbine plus cisplatin vs. Observation in resected non-small-cell lung cancer
    • Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97.
    • (2005) N Engl J Med , vol.352 , pp. 2589-2597
    • Winton, T.1    Livingston, R.2    Johnson, D.3    Rigas, J.4    Johnston, M.5    Butts, C.6
  • 11
    • 62849096370 scopus 로고    scopus 로고
    • Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebocontrolled trial
    • Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebocontrolled trial. Lancet 2009;373:1097-104.
    • (2009) Lancet , vol.373 , pp. 1097-1104
    • Dematteo, R.P.1    Ballman, K.V.2    Antonescu, C.R.3    Maki, R.G.4    Pisters, P.W.5    Demetri, G.D.6
  • 13
    • 84905029258 scopus 로고    scopus 로고
    • Comprehensive molecular profiling of lung adenocarcinoma
    • Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543-50.
    • (2014) Nature , vol.511 , pp. 543-550
  • 14
    • 84866894408 scopus 로고    scopus 로고
    • Comprehensive genomic characterization of squamous cell lung cancers
    • Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489: 519-25.
    • (2012) Nature , vol.489 , pp. 519-525
  • 16
    • 84861203302 scopus 로고    scopus 로고
    • EGFR-mutated oncogeneaddicted non-small cell lung cancer: Current trends and future prospects
    • Soria JC, Mok TS, Cappuzzo F, Janne PA. EGFR-mutated oncogeneaddicted non-small cell lung cancer: current trends and future prospects. Cancer Treat Rev 2012;38:416-30.
    • (2012) Cancer Treat Rev , vol.38 , pp. 416-430
    • Soria, J.C.1    Mok, T.S.2    Cappuzzo, F.3    Janne, P.A.4
  • 17
    • 77953541527 scopus 로고    scopus 로고
    • SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study
    • Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, et al. SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-9.
    • (2010) Lancet Oncol , vol.11 , pp. 521-529
    • Cappuzzo, F.1    Ciuleanu, T.2    Stelmakh, L.3    Cicenas, S.4    Szczésna, A.5    Juhász, E.6
  • 18
    • 84890896341 scopus 로고    scopus 로고
    • Gefitinib versus placebo in completely resected non-small-cell lung cancer: Results of the NCIC CTG BR19 study
    • Goss GD, O'Callaghan C, Lorimer I, Tsao MS, Masters GA, Jett J, et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol 2013;31: 3320-6.
    • (2013) J Clin Oncol , vol.31 , pp. 3320-3326
    • Goss, G.D.1    O'Callaghan, C.2    Lorimer, I.3    Tsao, M.S.4    Masters, G.A.5    Jett, J.6
  • 19
    • 84919339224 scopus 로고    scopus 로고
    • A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results
    • (suppl; abstr 7501)
    • Kelly K, Altroki NK, Eberhardt WEE, O'Brien MER, Spigel DR, Crino L, et al. A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results. J Clin Oncol 32:5s, 2014 (suppl; abstr 7501).
    • (2014) J Clin Oncol , vol.32 , Issue.S5
    • Kelly, K.1    Altroki, N.K.2    Eberhardt, W.E.E.3    O'Brien, M.E.R.4    Spigel, D.R.5    Crino, L.6
  • 21
    • 84879071011 scopus 로고    scopus 로고
    • Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
    • Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.
    • (2013) N Engl J Med , vol.368 , pp. 2385-2394
    • Shaw, A.T.1    Kim, D.W.2    Nakagawa, K.3    Seto, T.4    Crinó, L.5    Ahn, M.J.6
  • 22


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.